LMO

Table. 3.

Agreement and discrepancy rates classified by antibiotics between QMAC-dRAST and Vitek 2*

Bacterial species and antimicrobial agents No. of AST results EA (%) CA (%) VME (%) ME (%) mE (%)
GPC
Ampicillin 33 100.0 100.0 0.0 0.0 0.0
Ciprofloxacin 71 94.4 91.5 5.4 5.9 2.8
Clindamycin 71 95.8 93.0 5.9 0.0 5.6
Erythromycin 71 91.5 88.7 11.8 0.0 5.6
Gentamicin 71 100.0 94.4 0.0 0.0 5.6
Linezolid 104 99.0 99.0 0.0 1.0 0.0
Oxacillin 71 98.6 97.2 2.0 4.5 0.0
Penicillin 104 94.2 93.3 3.4 26.7 0.0
Rifampin 71 98.6 98.6 11.1 0.0 0.0
Tetracycline 71 94.4 94.4 13.6 2.0 0.0
Cotrimoxazole 71 95.8 91.5 4.0 10.9 0.0
Vancomycin 104 95.2 94.2 5.9 0.0 4.8
Total 913 96.3 94.5 4.8 2.5 2.1
GNR
Amikacin 98 100.0 100.0 0.0 0.0 0.0
Amoxicillin/Clavulanate 76 100.0 97.4 0.0 0.0 2.6
Ampicillin 76 100.0 98.7 0.0 0.0 1.3
Ampicillin/Sulbactam 9 88.9 88.9 0.0 16.7 0.0
Aztreonam 89 97.8 98.9 0.0 1.5 0.0
Cefazolin 76 100.0 92.1 0.0 0.0 7.9
Cefepime 98 94.9 91.8 0.0 2.9 6.1
Cefotaxime 85 96.5 95.3 0.0 3.7 2.4
Ceftazidime 101 93.1 91.1 4.2 5.3 4.0
Ciprofloxacin 98 99.0 95.9 0.0 1.5 3.1
Colistin 17 100.0 82.4 0.0 17.6 0.0
Ertapenem 76 98.7 98.7 0.0 0.0 1.3
Gentamicin 98 100.0 99.0 0.0 0.0 1.0
Imipenem 98 95.9 91.8 0.0 1.3 7.1
Meropenem 22 95.5 95.5 0.0 6.7 0.0
Minocycline 11 100.0 100.0 0.0 0.0 0.0
Piperacillin/Tazobactam 98 94.9 91.8 7.7 1.3 6.1
Cotrimoxazole 88 100.0 97.7 0.0 3.3 0.0
Total 1314 97.7 95.4 0.6 2.0 3.0

*For discordant results between QMAC-dRAST and Vitek 2, broth microdilution tests were performed to resolve such discrepancies.

Abbreviations: AST, antimicrobial susceptibility testing; CA, categorical agreement; VME, very major error; ME, major error; mE, minor error; GPC, gram-positive cocci; GNR, gram-negative rods.

Lab Med Online 2023;13:78~84 https://doi.org/10.47429/lmo.2023.13.2.78
© Lab Med Online